| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | BLUEPRINT MEDICINES CORP COM | 412,500 | 10,865,000 | 9.60% | ||
| 2 | SAGE THERAPEUTICS | 143,011 | 8,338,000 | 7.37% | ||
| 3 | LOXO ONCOLOGY INC COM | 251,500 | 7,155,000 | 6.32% | ||
| 4 | CYTOMX THERAPEUTICS INC COM | 321,023 | 6,700,000 | 5.92% | ||
| 5 | SPARK THERAPEUTICS INC | 145,000 | 6,570,000 | 5.80% | ||
| 6 | BLUEBIRD BIO INCORPORATED | 100,000 | 6,422,000 | 5.67% | ||
| 7 | AGIOS PHARMACEUTICALS INC | 96,500 | 6,265,000 | 5.54% | ||
| 8 | MYOKARDIA INC | 403,872 | 5,921,000 | 5.23% | ||
| 9 | GENOMIC HEALTH INC COM | 165,000 | 5,808,000 | 5.13% | ||
| 10 | ILLUMINA INC | 30,000 | 5,758,000 | 5.09% | ||
| 11 | ALNYLAM PHARMACEUTICALS INC | 60,000 | 5,648,000 | 4.99% | ||
| 12 | EPIZYME INC COM | 332,500 | 5,327,000 | 4.71% | ||
| 13 | VOYAGER THERAPEUTICS INC | 236,862 | 5,187,000 | 4.58% | ||
| 14 | ILLUMINA INC | 20,000 | 3,839,000 | 3.39% | Call | |
| 15 | BIOGEN INC | 9,000 | 2,757,000 | 2.44% | ||
| 16 | FOUNDATION MEDICINE INC COM | 115,000 | 2,422,000 | 2.14% | ||
| 17 | GENMARK DIAGNOSTICS INC COM | 310,000 | 2,406,000 | 2.13% | ||
| 18 | BRISTOL MYERS SQUIBB CO | 32,164 | 2,213,000 | 1.96% | ||
| 19 | GLOBAL BLOOD THERAPEUTICS IN COM | 65,000 | 2,101,000 | 1.86% | ||
| 20 | INVITAE CORP | 250,000 | 2,053,000 | 1.81% | ||
| 21 | KITE PHARMA INCORPORATED | 30,000 | 1,849,000 | 1.63% | ||
| 22 | DEXCOM | 17,000 | 1,392,000 | 1.23% | ||
| 23 | BLUEBIRD BIO INCORPORATED | 20,000 | 1,284,000 | 1.13% | Call | |
| 24 | ORASURE TECHNOLOGIES INC | 170,000 | 1,095,000 | 0.97% | ||
| 25 | Oxford Immunotec Global PLC | 75,000 | 863,000 | 0.76% | ||
| 26 | JUNO THERAPEUTICS INCORPORATED | 17,500 | 769,000 | 0.68% | ||
| 27 | Atara Biotherapeutics Inc | 25,000 | 660,000 | 0.58% | ||
| 28 | MEDIDATA SOLUTIONS INC | 10,000 | 493,000 | 0.44% | ||
| 29 | TROVAGENE INC COM NEW | 70,000 | 378,000 | 0.33% | ||
| 30 | AGIOS PHARMACEUTICALS INC | 5,000 | 325,000 | 0.29% | Call | |
| 31 | FOUNDATION MEDICINE INC COM | 15,000 | 316,000 | 0.28% | Call |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001172661-16-002454, filed 2016.02.08).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
